The U.S. Food and Drug Administration issued a Complete Response Letter to Chicago’s Levo Therapeutics for the company’s New Drug Application for LV-101, which is being developed as a treatment for hyperphagia (excessive overeating), anxiousness and distress associated with Prader-Willi syndrome (PWS).
If you are not happy with the results below please do another search
50 search results for:
Ionis Pharmaceuticals announced that Roche, the company’s partner firm, is designing a new Phase II trial that would assess the effectiveness of tominersen in younger adult patients diagnosed with Huntington’s disease.
One week after expanding the company’s neurodegenerative diseases partnership with Bristol Myers Squibb, Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
A World Health Organization committee urged COVID-19 vaccine manufacturers on January 18 to provide the data it requires in order to list their shots for emergency use, saying the delays were affecting equitable vaccine access.
Fully integrated biopharmaceutical solutions organization Syneos Health announced the appointment of two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors.
Healthline Media launched a suite of seven health condition communities through its new brand, Bezzy.
Endo International agreed to pay up to $65 million to resolve claims by the state of Florida and local governments that the drugmaker helped fuel the U.S. opioid epidemic.
Merck & Co. Inc. and partner Ridgeback Biotherapeutics LP said on January 18 they had signed an agreement with the United Nations Children’s Fund (UNICEF) to supply up to 3 million courses of their COVID-19 antiviral pill.
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms.
Moderna Inc.’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Jan. 17.